Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial. Nagpal, S., Recht, C., Imtiaz, U., Bertrand, S., Thomas, B., Ajlan, A., Pena, J., Gershon, M., Kunz, P. L., Li, G., Recht, L. AMER SOC CLINICAL ONCOLOGY. 2014
View details for DOI 10.1200/jco.2014.32.15_suppl.2096
View details for Web of Science ID 000358613202760